Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (3106)	5/25/1999 9:44:00 PM
From: EZLibra	Read Replies (3) \| Respond to of 3702

Insightful and thought-provoking as usual, Maurice. Thank you. I would like to add that prevailing opinion is that about half of cancer therapy in the U.S. is off-label use. The ongoing brain cancer trial will entail approximately 40,000 citizens per year, including many other kinds of brain cancers. My nearest and dearest died of NHL but it had gotten into the central nervous system and technically become brain cancer so she would have qualified for TNT (Cotara) also. Furthermore the liver, prostate, and pancreatic cancers being treated at the Mexico NIH are highly vascularized and relatively well contained neoplasms which should respond favorably to Cotara. Most solid tumors seem susceptible to treatment. I predict that if FDA allows accelerated acceptance we will see a sea change in cancer therapy (removing the threat of tort lawyers should do wonders). I don't think it will take that long. OT, Couldn't help posting...I just figured the inmates have been running these threads long enough.